Latest News about Biotech
Recent news which mentions Biotech
From Benzinga
Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug
October 17, 2024
From Benzinga
From Benzinga
Novo Nordisk's Weight Loss Drug Ozempic Associated With Reduced Opioid, Alcohol Use Disorder Incidences, Study Shows
October 17, 2024
From Benzinga
From Benzinga
EXCLUSIVE: Adial Pharmaceuticals Secures Additional US Patent Expanding Intellectual Property Protection Around Its Alcohol Use Disorder Candidate
October 17, 2024
From Benzinga
'Miracle' Weight Loss Drug Ozempic And Similar Drugs Reduce Alcohol And Opioid Overdose, Study Reveals
October 17, 2024
From Benzinga
Powerful Leadership Transition to Optimize Highly Promising AI Platform RenovaroCube for Multi-Cancer Early Detection & Monitoring: Stock Symbol: RENB
October 16, 2024
From PRLog
Scilex Explores Strategic Options, Analyst Initiates On Blockbuster Potential For Sciatica Pain Candidate
October 16, 2024
From Benzinga
Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock
October 16, 2024
From Benzinga
Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch
October 16, 2024
From Benzinga
Johnson & Johnson's MedTech Challenges Loom Amid Chinese Market Pressures And Orthopedics Overhaul, Analysts Say
October 16, 2024
From Benzinga
GSK Seeks FDA Approval For Oral Antibiotic For Urinary Tract Infections, Probably First In New Class In Over 20 Years
October 16, 2024
From Benzinga
Wave Life Sciences Reveals RNA Editing Breakthrough, Reports First-Ever Clinical Proof-Of-Mechanism In Humans
October 16, 2024
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.